Dennis Karounos is an Endocrinology/Metabolic physician affiliated with University of Kentucky. OpenAlex indexes 41 publications with 5,513 citations (h-index 20); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1101 Veterans Dr
Lexington, KY 405022235
Telephone
859-233-4511Registry record last updated 13 Apr 2012.
Clinical trials
- Veterans Inpatient Insulin Study and Transition to Outpatient Therapy
Sponsor: Dennis G. Karounos, M.D.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20212 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 1997–2022 per NIH RePORTER. The latest:
- Mechanisms linking obesity and abdominal aortic aneurysm
Va Medical Center - Lexington, Ky
FY2022I01BX004275
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
The Lancet Diabetes & Endocrinology
2023 - Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
The Lancet Diabetes & Endocrinology
2023 - Antisense Oligonucleotide Targeting Hepatic Serum Amyloid A Limits the Progression of Angiotensin II-Induced Abdominal Aortic Aneurysm Formation
bioRxiv (Cold Spring Harbor Laboratory)
2023
Similar KOLs
Other experts from the same institution or the same specialty.
David Moliterno, MD
University of Kentucky
Robert Dipaola
University of Kentucky
Darwin Conwell, MD
University of Kentucky
Phillip Tibbs
University of Kentucky
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”